PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease ReportsHemostatic disorders
MeSH D020141 - hemostatic disorders
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D014652:Vascular diseases
1 Company
1 Drug
$
Success rate
D006474:Hemorrhagic disorders
1 Company
1 Drug
$
Success rate
D020141: 
Hemostatic disorders
1 Company
1 Drug
$
Success rate
D003449:Cryoglobulinemia
4 Companies
6 Drugs
$
Success rate
D004535:Ehlers-danlos syndrome
0 Companies
0 Drugs
Success rate
D006392:Cavernous hemangioma
0 Companies
0 Drugs
Success rate
D008258:Waldenstrom macroglobulinemia
24 Companies
5 Drugs
$
Success rate
D009101:Multiple myeloma
81 Companies
34 Drugs
$
Success rate
D011561:Pseudoxanthoma elasticum
0 Companies
0 Drugs
Success rate
D011694:Hyperglobulinemic purpura
0 Companies
0 Drugs
Success rate
D012614:Scurvy
9 Companies
18 Drugs
$
Success rate
D012790:Shwartzman phenomenon
0 Companies
0 Drugs
Success rate
D013683:Hereditary hemorrhagic telangiectasia
0 Companies
0 Drugs
Success rate
D011695:Iga vasculitis
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
No Data
Clinical Trials
Historical Success Rate
Phase 1
100%
1/1
Phase 2
0%
0/1
Phase 3
100%
1/1
Approved: 1Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Bristol Myers Squibb
Idecabtagene vicleucel
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use